

2 **COVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in saliva**

3

4 **Authors**

5 Pranay R. Randad^{1*}, Nora Pisanic^{1*}, Kate Kruczynski¹, Yukari C. Manabe^{2,3}, David Thomas²,
6 Andrew Pekosz^{1,4}, Sabra L. Klein^{4,5}, Michael J. Betenbaugh⁶, William A. Clarke³, Oliver
7 Laeyendecker^{2,7,8}, Patrizio P. Caturegli^{3,9}, H. Benjamin Larman^{3,9}, Barbara Detrick^{3,9}, Jessica K.
8 Fairley¹⁰, Amy C. Sherman¹¹, Nadine Rouphael¹¹, Srilatha Edupuganti¹¹, Douglas A. Granger¹²,
9 Steve W. Granger¹³, Matthew Collins¹¹, Christopher D. Heaney^{1,6,14}

10

11 **Affiliations**

12 *Contributed equally

13 ¹Department of Environmental Health and Engineering, Bloomberg School of Public Health,
14 Johns Hopkins University, Baltimore, Maryland, USA

15 ²Division of Infectious Diseases, Department of Medicine, School of Medicine, Johns Hopkins
16 University, Baltimore, Maryland, USA

17 ³Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, Maryland,
18 USA

19 ⁴Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health,
20 Johns Hopkins University, Baltimore, Maryland, USA

21 ⁵Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns
22 Hopkins University, Baltimore, Maryland, USA

23 ⁶Department of Chemical and Biomolecular Engineering, Whiting School of Engineering, Johns
24 Hopkins University, Baltimore, Maryland, USA

25 ⁷Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University,
26 Baltimore, Maryland, USA

27 ⁸Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National
28 Institutes of Health, Baltimore, Maryland, USA

29 ⁹Division of Immunology, Department of Pathology, School of Medicine, Johns Hopkins
30 University, Baltimore, Maryland, USA

31 ¹⁰Hubert Department of Global Health, Emory University Rollins School of Public Health,
32 Atlanta, GA, USA

33 ¹¹The Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of
34 Medicine, Emory University School of Medicine, Decatur, Georgia, USA

35 ¹²Institute for Interdisciplinary Salivary Bioscience Research, University of California Irvine,
36 Irvine, California, USA

37 ¹³Salimetrics, LLC, Carlsbad, California, USA

38 ¹⁴Department of International Health, Bloomberg School of Public Health, Johns Hopkins
39 University, Baltimore, Maryland, USA

40

41

42 **Keywords**

43 SARS-CoV-2, COVID-19, saliva, oral fluid, serology, antibody test, multiplex

44

45 **40-word summary**

46 A multiplex immunoassay to detect SARS-CoV-2-specific antibodies in saliva performs with
47 high diagnostic accuracy as early as ten days post-COVID-19 symptom onset. Highly sensitive
48 and specific salivary COVID-19 antibody assays could advance broad immuno-surveillance
49 goals in the USA and globally.

50

51 **Author Contributions**

52 All authors reviewed and edited all sections of the article. P.R.R. and N.P. wrote the first draft of
53 the manuscript. K.K. and N.P handled laboratory logistics and generated data. N.P. and P.R.R.
54 analyzed and summarized the data. A.P. provided input on study design and edited the
55 manuscript. M.J.B., S.W.G., D.A.G. provided input on antigen selection, assay design, and
56 interpretation of results. Y.C.M and D.T. provided input on study design and interpretation of
57 results. B.D. provided input on interpretation of results. W.A.C, O.L., P.P.C., and B.L. shared
58 samples and data for the analysis and provided input on interpretation of results. M.H.C
59 developed project concept. M.H.C, N.R., J.F., and A.C.S. led and coordinated specimen
60 collection efforts and reviewed and edited the article. C.D.H. developed project concept and
61 guided the laboratory work.

62

63 **Conflict of interest**

64 In the interest of full disclosure, D.A.G. is founder and Chief Scientific and Strategy Advisor at
65 Salimetrics, LLC and Salivabio, LLC and these relationships are managed by the policies of the
66 committees on conflict of interest at Johns Hopkins School of Medicine and the University of
67 California at Irvine. N.R. received funds from Sanofi Pasteur, Quidel, Merck and Pfizer.

68

69 **Acknowledgements**

70 We would like to thank the participants who provided saliva and blood specimens that were used
71 in this study to help develop and validate the multiplex SARS-CoV-2 antibody assays. We thank
72 the faculty and staff team of The Hope Clinic for a dedicated effort in recruiting subjects and
73 collecting specimens. We thank Dr. Yerun Zhu and Dr. Daniel Espinoza for assistance with
74 laboratory operations

75

76 **Sources of funding**

77 Funding for this study was provided by the Johns Hopkins University Provost's Office and the
78 FIA Foundation. P.R.R., N.P., K.K., and C.D.H. were supported by a gift from the GRACE
79 Communications Foundation. C.D.H., N.P., and B.D. were additionally supported by National
80 Institute of Allergy and Infectious Diseases (NIAID) grants R21AI139784 and R43AI141265,
81 and National Institute of Environmental Health Sciences (NIEHS) grant R01ES026973. C.D.H.
82 was also supported by NIAID grant R01AI130066 and NIH grant U24OD023382. A.P. and
83 S.L.K. were supported by NIH/NIAID Center of Excellence in Influenza Research and
84 Surveillance contract HHS N2772201400007C. O.L. was supported by the Division of
85 Intramural Research, NIAID. The funders had no role in study design, data analysis, decision to
86 publish, or preparation of the manuscript.

87

88 **Ethical Statement**

89 This study has been approved by the Johns Hopkins Bloomberg School of Public Health
90 Institutional Review Board (IRB) (IRB No. IRB00012253) Johns Hopkins Medicine IRB (IRB

- 91 No. IRB00247886) and by the Emory University Institutional Review Board (IRB No.
92 00110683).

93 **Abstract**

94 Non-invasive SARS-CoV-2 antibody testing is urgently needed to estimate the incidence
95 and prevalence of SARS-CoV-2 infection at the general population level. Precise knowledge of
96 population immunity could allow government bodies to make informed decisions about how and
97 when to relax stay-at-home directives and to reopen the economy. We hypothesized that salivary
98 antibodies to SARS-CoV-2 could serve as a non-invasive alternative to serological testing for
99 widespread monitoring of SARS-CoV-2 infection throughout the population. We developed a
100 multiplex SARS-CoV-2 antibody immunoassay based on Luminex technology and tested 167
101 saliva and 324 serum samples, including 134 and 118 negative saliva and serum samples,
102 respectively, collected before the COVID-19 pandemic, and 33 saliva and 206 serum samples
103 from participants with RT-PCR-confirmed SARS-CoV-2 infection. We evaluated the correlation
104 of results obtained in saliva vs. serum and determined the sensitivity and specificity for each
105 diagnostic media, stratified by antibody isotype, for detection of SARS-CoV-2 infection based
106 on COVID-19 case designation for all specimens. Matched serum and saliva SARS-CoV-2
107 antigen-specific IgG responses were significantly correlated. Within the 10-plex SARS-CoV-2
108 panel, the salivary anti-nucleocapsid (N) protein IgG response resulted in the highest sensitivity
109 for detecting prior SARS-CoV-2 infection (100% sensitivity at ≥ 10 days post-SARS-CoV-2
110 symptom onset). The salivary anti-receptor binding domain (RBD) IgG response resulted in
111 100% specificity. Among individuals with SARS-CoV-2 infection confirmed with RT-PCR, the
112 temporal kinetics of IgG, IgA, and IgM in saliva were consistent with those observed in serum.
113 SARS-CoV-2 appears to trigger a humoral immune response resulting in the almost
114 simultaneous rise of IgG, IgM and IgA levels both in serum and in saliva, mirroring responses
115 consistent with the stimulation of existing, cross-reactive B cells. SARS-CoV-2 antibody testing

116 in saliva can play a critically important role in large-scale “sero”-surveillance to address key
117 public health priorities and guide policy and decision-making for COVID-19.

118 **Introduction**

119 The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory
120 syndrome virus 2 (SARS-CoV-2), has caused >5.4 million COVID-19 cases and >344,000
121 deaths, as of May 24, 2020, involving all populated continents.¹ The USA accounts for >1.6
122 million COVID-19 cases and >97,000 deaths and the outbreak has expanded from urban to rural
123 areas of the country.¹ There is a critical need to perform broad-scale population-based testing to
124 improve COVID-19 prevention and control efforts. Some have even recommended national
125 testing at repeated time points to improve understanding of the spatio-temporal dynamics of
126 transmission, infection, and herd immunity.^{2,3} Currently, population-level antibody testing is
127 largely performed using blood, with preliminary seroprevalence study estimates ranging from
128 2.8% in Santa Clara County, California,⁴ 4.65% in Los Angeles County, California,⁵ 21% in
129 New York City,⁶ 11.5% in Robbio Italy,⁷ and 14% in Gangel, Germany.⁸ Achieving such
130 comprehensive national testing goals will be challenging by relying only on traditional blood-
131 based diagnostic specimens as these may be considered too invasive, uncomfortable, or
132 unacceptable, particularly among vulnerable and susceptible groups.⁹⁻¹²

133 In addition to molecular COVID-19 diagnostics, accurate serological tests can identify
134 individuals who have mounted an antibody response to SARS-CoV-2 infection. These tests are
135 needed in platforms that can be deployed in large numbers to describe changes in population
136 level immunity at different geographical scales and over time. Such serological testing could
137 guide “back-to-work” risk mitigation strategies^{2,3}, particularly if evidence continues to emerge
138 suggesting that robust SARS-CoV-2 antibody responses might confer protection from repeated
139 infection.^{13,14}

140 Saliva harvested from the space between the gums and the teeth is enriched with gingival
141 crevicular fluid (GCF). The composition of GCF (hereafter referred to as “saliva”) resembles that
142 of serum, and is enriched with antibodies.¹⁵⁻²⁴ Thus, sampling saliva with an appropriate
143 collection method is an attractive non-invasive approach for antibody-based diagnostic
144 techniques. We have previously demonstrated the utility of saliva-based serology testing for the
145 diagnosis, surveillance, and study of infection by multiple viral pathogens.^{21,22} Development of
146 improved antibody assays to detect prior infection with SARS-CoV-2 has been identified as one
147 of the top unmet needs in the ongoing COVID-19 pandemic response.^{2,3} Precise knowledge of
148 SARS-CoV-2 infection at the individual level can potentially inform clinical decision-making,
149 whereas at the population level, precise knowledge of prior infection, immunity, and attack rates
150 (particularly asymptomatic infection) is needed to prioritize risk management decision-making
151 about social distancing, treatments, and vaccination (once the latter two become available).²⁵ If
152 saliva can support measurements of both the presence of SARS-CoV-2 RNA²⁶⁻²⁸ as well as
153 antibodies against SARS-CoV-2, this sample type could provide an important opportunity to
154 monitor individual and population-level SARS-CoV-2 transmission, infection, and immunity
155 dynamics over place and time.

156 Prior studies have shown that antibodies to SARS-CoV-2 nucleocapsid protein (N), spike
157 protein (S), and the receptor binding domain (RBD) are elevated in serum around 10-18 days
158 following SARS-CoV-2 infection.^{14,29-32} Many ELISA, point-of-care (POC), and lateral flow IgG
159 assays for detecting prior SARS-CoV-2 infection that are currently available show a wide range
160 in diagnostic performance. The sensitivity of the assays improves when samples are collected
161 later after the onset of infection, from <20% sensitivity at <5 days to approximately 100%
162 sensitivity at 17 to 20 days from symptom onset.³³⁻³⁵

163 In this study, we aimed to determine whether salivary SARS-CoV-2-specific antibody
164 responses would identify prior SARS-CoV-2 infection with similar sensitivity and specificity as
165 serum and whether salivary antibody testing would reflect the temporal profiles observed in
166 serum. The objectives of this study were: (1) to develop and validate a multiplex bead-based
167 immunoassay for detection of SARS-CoV-2-specific IgG, IgA, and IgM responses; (2) to
168 describe the assay performance using saliva compared to using serum specimens; (3) to identify
169 SARS-CoV-2 antigens that could result in high sensitivity and specificity to identify antibody
170 responses to prior SARS-CoV-2 infection; and (4) to compare the antibody kinetics in saliva to
171 those in serum by time since onset of COVID-19 symptoms.

172

173 **Methods**

174 *Sources of saliva and serum*

175 Saliva and serum samples were provided by collaborators from Emory University from
176 patients in three settings: 1) PCR-confirmed COVID-19 cases while admitted to the hospital; 2)
177 confirmed COVID-19 cases we invited to donate specimens after recovering from their acute
178 illness; and 3) patients with symptoms consistent with COVID-19 being tested at an ambulatory
179 testing center donated specimens at the time of testing and/or at a follow-up convalescent phase
180 research visit. Collaborators at Johns Hopkins University provided: 1) serum samples from
181 patients presenting with COVID-19-like symptoms such as fever, cough, dyspnea who were
182 recruited in both inpatient and outpatient clinical care sites; and 2) negative saliva and serum
183 samples collected prior to the COVID-19 pandemic. Participants provided verbal and / or written
184 informed consent and provided saliva and blood specimens for analysis. Whenever possible,
185 remnant clinical blood specimens were used. Basic data on days since symptom onset were

186 recorded for all participants as were results of COVID-19 molecular testing. Participation in
187 these studies was voluntary and the study protocols have been approved by the respective
188 Institutional Review Boards.

189

190 *Saliva and blood sample collection*

191 Saliva samples were collected by instructing participants to gently brush their gum line
192 with an OraCol S14 saliva collection device (Malvern Medical Developments, UK) for 1-2
193 minutes, or until saturation. This saliva collection method specifically harvests GCF, which is
194 enriched with primarily IgG antibody derived from serum.¹⁸ The saturated sponge was then
195 inserted into the storage tube, capped, and stored at 4°C until processing whenever possible.
196 Saliva was separated from the OraCol S14 swabs through centrifugation (10 min at 1,500 g) and
197 transferred into the attached 2 mL cryovial. Samples were heat-inactivated at 60°C for 30
198 minutes and then shipped to the lab on dry ice. Blood samples were collected into ACD (acid,
199 citrate, dextrose) or serum separator tubes (SST) and processed according to each clinical lab's
200 procedure. Plasma/serum was also heat inactivated at 60°C for 30 minutes, aliquoted into 2mL
201 cryovials, and stored at ≤20°C until analyzed. Only de-identified serum or plasma and saliva
202 aliquots including limited metadata (days since symptom onset and SARS-CoV-2 RT-PCR status
203 [ever positive or negative]) were shared for this study.

204

205 *Multiplex magnetic microparticle (“bead”)-based SARS-CoV-2 saliva immunoassay*

206 Ten SARS-CoV-2 antigens were obtained commercially or from collaborators at Icahn
207 School of Medicine at Mount Sinai (**Table 1**).³⁶ This included four SARS-CoV-2 receptor
208 binding domain (RBD), one ectodomain (ECD) protein containing the S1 and S2 subunit of the

209 spike protein, two S1 subunits, one S2 subunit, and two N proteins. Each SARS-CoV-2 antigen,
210 along with one SARS-CoV-1 antigen (NAC SARS 2002 N) and one human coronavirus (hCoV)-
211 229E antigen (Sino Biol. hCoV 229E ECD), were covalently coupled to magnetic microparticles
212 (MagPlex microspheres, Luminex) as described previously (**Table 1**).^{21,22} Along with a control
213 bead, conjugated with bovine serum albumin (BSA), the multiplex panel included a total of 13
214 bead sets (10 bead sets coupled to SARS-CoV-2 antigens, one to SARS-CoV-1 antigen, one to
215 hCoV-229E antigen, and one control bead coupled to BSA). Coupling of antigens to beads was
216 confirmed using antibody against the antigen or against the tag (e.g. anti-His(6) tag antibody), if
217 present (**Table 1**), followed by a species-specific R-phycoerythrin (PE)-labelled antibody and
218 was considered successful if the median fluorescence intensity (MFI [a.u.]) was >10,000 at 1
219 µg/mL of antigen-specific antibody (except the BSA-conjugated bead set). Saliva samples were
220 centrifuged (5 minutes at 20,000g, 20°C), and 10 µL of saliva supernatant was added to 40 µL of
221 assay buffer (phosphate-buffered saline with 0.05% Tween20, 0.02% sodium azide and 1%
222 BSA) containing 1,500 beads of each bead set per microplate well. The plate was covered and
223 incubated at room temperature for 1 hour on a plate shaker at 500 rpm. Beads were washed twice
224 with 200 µL PBST and 50 µL of PE-labeled anti-human IgG, IgA or IgM diluted 1:100 in assay
225 buffer were added, and the plate was incubated again for 1 hour on a plate shaker at 500 rpm.
226 Beads were washed as above and then suspended in 100 µL of assay buffer. Finally, the MFI of
227 each bead set was measured on a Bio-Plex® immunoassay instrument (Bio-Rad Laboratories,
228 Hercules, CA). The same protocol was used for serum and plasma samples, except that serum
229 and plasma samples were tested at a final dilution of 1:1000 in bead mix and assay buffer
230 compared to a final dilution of 1:5 for saliva. A subset of 47 saliva samples were tested in
231 duplicate and in a masked fashion to determine intra-assay variability (same 96 well plate) and

232 inter-assay variability (different 96 well plates on different days), and at least 2 blanks (assay
233 buffer) were included on each plate for background fluorescence subtraction.

234

235 *Statistical analysis*

236 The median fluorescence intensity (MFI) measured using the BSA beads was subtracted
237 from each blank-subtracted antigen-specific MFI signal for each sample to account for non-
238 specific binding of antibodies to beads. The average MFI was used for samples that were tested
239 in duplicate (n=47) or triplicate. Wilcoxon-Mann-Whitney test was used to compare the median
240 MFI between samples collected <10 days post symptom onset and negatives, and between
241 samples collected \geq 10 days post symptom onset and negatives, for each antigen in the multiplex.
242 The average intra- and inter-assay variability was evaluated by determining the coefficient of
243 variation (CV%) of a subset of 47 samples that were tested in duplicate (intra) and on different
244 days and plates (inter). Pearson's correlation was used to determine the correlation between
245 antigen-specific IgG, IgA, and IgM MFI in matched saliva and serum / plasma samples collected
246 from the same person at the same time point (n=28). The average MFI of all saliva samples from
247 known uninfected individuals (pre-Covid-19) plus three standard deviations for each antigen-
248 specific IgG, IgA, and IgM were used to establish the cut-off values for a negative result. The
249 corresponding procedure was used for serum samples. Because the prior hCoV infection status
250 for saliva and serum samples was not known, the MFI cut-off values were not calculated for anti-
251 Sino Biol. hCoV 229E ECD IgG, IgA, and IgM. Sensitivity and specificity for detecting samples
252 from confirmed RT-PCR positive individuals and for samples from individuals obtained prior to
253 the COVID-19 pandemic were determined for each antigen/isotype pair (IgG, IgM and IgA) in
254 saliva and in serum. Locally weighted regression (LOESS) was used to visualize and compare

255 the temporal kinetics of saliva and serum antigen-specific IgG, IgA, and IgM responses among
256 individuals with RT-PCR confirmed prior SARS-CoV-2 infection post symptom onset.

257

258 **Results**

259 *Saliva and serum samples*

260 A total of 33 saliva samples and 206 serum samples were collected from 33 and 59
261 individuals, respectively, with RT-PCR confirmed prior SARS-CoV-2 infection (**Table 2**).
262 Information on days post symptom onset was collected for each positive participant. A total of
263 134 saliva samples (from 2012 to early 2019) and 112 serum samples (from 2016)³⁷ were
264 collected from participants enrolled in cohort studies prior to the start of the COVID-19
265 pandemic and were designated as negative samples (pre-COVID-19 pandemic) (**Table 2**).

266

267 *SARS-CoV-2 antigen-specific IgG, IgA, and IgM cut-off values*

268 The multiplex immunoassay, comprised of ten SARS-CoV-2 antigens (2 N proteins, 1
269 ECD protein, four RBD proteins, two S1 subunits, and one S2 subunit), one SARS-CoV-1
270 antigen (NAC SARS CoV 2002 N), and one hCoV-229E antigen (Sino Biol. hCoV 229E ECD)
271 was used to test a total of 167 saliva samples from 150 individuals and 324 serum samples from
272 171 individuals. The range, median, mean, standard deviation, and derived MFI cut off value for
273 each saliva and serum SARS-CoV-2 antigen-specific IgG, IgA, and IgM stratified by negative
274 samples, samples collected <10 days, and ≥ 10 days post SARS-CoV-2 symptom onset are
275 provided in **Supplementary Table 1** and **Supplementary Table 2**. Saliva collected at ≥ 10 days
276 post symptom onset had significantly elevated IgG levels (median MFI) against all SARS-CoV-2
277 antigens compared to negative saliva samples (**Supplementary Table 1**). Serum collected at ≥ 10

278 days post symptom onset had significantly elevated IgG, IgA, and IgM levels (median MFI)
279 against all SARS-CoV-2 antigens compared to negative sera.

280

281 *Correlation between saliva and serum SARS-CoV-2-specific IgG*

282 Twenty-eight participants provided matched saliva and serum samples that were collected
283 during the same visit (n=6 negative and n=22 RT-PCR confirmed SARS-CoV-2 infection
284 matched saliva and serum samples). Antigen-specific IgG levels in matched saliva and serum
285 samples were significantly correlated for all SARS-CoV-2 and SARS-CoV-1 antigens (**Figure**
286 **1**). Antigen-specific IgA in matched saliva and serum samples were modestly correlated with
287 significance detected only for a subset of antigens: GenScript N, Sino Biol. N, Sino Biol. ECD,
288 GenScript S1, and NAC SARS 2002 N (**Figure 2**). Antigen-specific IgM in matched saliva and
289 serum samples were also significantly correlated for all SARS-CoV-2 and SARS-CoV-1
290 antigens, although the correlation was weaker than for IgG (**Figure 3**).

291

292 *Saliva: Sensitivity and specificity*

293 In saliva, the sensitivity to detect SARS-CoV-2 infection increased among saliva samples
294 collected ≥ 10 days post symptom onset compared to those collected < 10 days post symptom
295 onset, for all isotypes (IgG, IgA, and IgM)(**Figure 4**). The highest sensitivity (100%) was
296 achieved with GenScript N-coupled beads in saliva samples collected ≥ 10 days post symptom
297 onset. All (28/28) individuals with RT-PCR confirmed prior SARS-CoV-2 infection had salivary
298 anti-GenScript N IgG levels above the cut-off (**Figure 4**). Specificity to classify negative saliva
299 samples correctly ranged from 98% to 100% for SARS-CoV-2 IgG. Mt. Sinai's RBD resulted in
300 the highest specificity (100%). All (134/134) negative saliva samples resulted in MFI values

301 below the cut-off (mean + 3 SD) for anti-Mt. Sinai RBD IgG levels. The highest combined
302 sensitivity and specificity was achieved with GenScript N (100% sensitivity and 99% specificity
303 at ≥ 10 days post symptom onset).

304 While IgA and IgM against SARS-CoV-2 also remained equivalent or increased among
305 saliva samples collected ≥ 10 days compared to < 10 days post symptom onset, the sensitivity to
306 detect prior SARS-CoV-2 infection remained low (**Figure 4**). For SARS-CoV-2 specific IgA,
307 sensitivity ranged from 4% with NAC S2 to 61% with Sino Biol. ECD. For IgM, sensitivity
308 ranged from 0% with NAC S2 to 65% with GenScript S1. Specificity for IgA ranged from 42%
309 with GenScript S1 to 100% with NAC S1 and S2. The highest combined sensitivity and
310 specificity for IgA was obtained with Sino Biol. ECD (61% sensitivity ≥ 10 days post symptom
311 onset and 96% specificity). For IgM, specificity ranged from 96% (GenScript RBD [i]) to 99%
312 (Sino Biol. ECD, GenScript S1, and NAC S2). The highest combined sensitivity and specificity
313 for IgM was reached with GenScript S1 (65% sensitivity, 99% specificity).

314

315 *Serum: Sensitivity and specificity*

316 In serum, the sensitivity to detect SARS-CoV-2 infection improved among serum
317 samples collected ≥ 10 days compared to < 10 days post symptom onset, for all isotypes (IgG,
318 IgA, and IgM)(**Figure 5**). For anti-SARS-CoV-2 IgG, the highest sensitivity (92%) achieved
319 with Mt. Sinai and Sino Biol. RBD using sera collected ≥ 10 days post symptom onset (96/104
320 samples from individuals with RT-PCR confirmed prior SARS-CoV-2 infection had IgG levels
321 against these antigens above the cut-offs) (**Figure 5**). Specificity ranged from 96%-99% for anti-
322 SARS-CoV-2 IgG. The highest combined sensitivity and specificity was achieved with Mt.
323 Sinai's RBD (92% sensitivity and 99% specificity at ≥ 10 days post symptom onset)

324 For anti-SARS-CoV-2 IgA and IgM, sensitivity ranged from 0% to 45% when using
325 serum samples collected <10 days post-COVID-19 symptom onset; sensitivity was higher
326 overall when detecting IgA compared to IgM. The sensitivity improved significantly with several
327 antigens (predominantly RBD), when samples collected ≥ 10 days post-COVID-19 symptom
328 onset were tested (**Figure 5**). When testing these sera, the highest sensitivity to detect IgA was
329 reached using GenScript RBD (h) antigen (95%; 99/104 samples above the cutoff) but several
330 additional antigens also performed with high sensitivity. In contrast, only two antigens (Mt. Sinai
331 RBD and GenScript RBD [h]) in the assay reached sensitivities above 90% when detecting anti-
332 SARS-CoV-2 IgM. Specificity ranged from 96%-99% for both anti-SARS-CoV-2 IgA and IgM.
333 The highest combined sensitivity and specificity for detecting IgA and IgM was reached using
334 Mt. Sinai's RBD (as was the case for serum IgG) but also when using NAC's SARS 2002 N
335 antigen (**Figure 5**).

336

337 *Temporal kinetics of SARS-CoV-2 specific IgG, IgA, and IgM responses in serum compared to*
338 *saliva*

339 The temporal kinetics of antigen-specific IgG, IgA, and IgM responses in serum and in
340 saliva are shown in **Figure 6**. Also shown are the cut-offs for each isotype (IgG, IgA, and IgM)
341 in serum and in saliva (dashed lines). The temporal kinetics and magnitude of the antigen-
342 specific IgG and IgA responses in saliva generally correlate with those detected in serum. The
343 IgM response is significantly lower in magnitude (MFIs) in saliva compared to serum, which is
344 expected and consistent with the lower relative concentration of total IgM in saliva compared to
345 total IgA and IgG concentrations in saliva.

346 In serum, the SARS-CoV-specific IgA levels across individuals consistently cross the
347 cut-off (dashed lines), thus indicating seroconversion, several days before IgG and IgM. IgG and
348 IgM seroconversion in serum seem to occur approximately at the same time.

349 Even though saliva IgA levels increase closely after IgG levels, the SARS-CoV-2-
350 specific IgA response often does not cross the cut-off, indicative of the low observed sensitivity.
351 IgM levels in saliva are low and LOESS regression lines generally remain under the cut-off for
352 most antigens in the multiplex assay. However, in saliva, the antigen-specific IgG response
353 consistently crosses the cut-off around 10 days post symptom onset, i.e. approximately 15 days
354 post infection, similar, to the time of IgG seroconversion in serum. The anti-SARS-CoV-2 IgG
355 response in saliva thus appears to mimic seroconversion in serum.

356

357 *Reactivity of antibodies with SARS-CoV-1 and hCoV proteins following SARS-CoV-2 infection*

358 We sought to evaluate reactivity of SARS-CoV-1 and hCoV proteins in samples from
359 COVID-19 cases. For IgG, all convalescent phase saliva from COVID-19 cases (28/28; 100%)
360 reacted with the NAC SARS 2002 N protein. Similarly, 89% and 95% of convalescent sera from
361 COVID-19 cases reacted with the NAC SARS 2002 N protein for IgG and IgA, respectively.
362 The median MFI for salivary IgG and IgA, and serum IgG, IgA, and IgM, to NAC SARS 2002 N
363 was significantly elevated among samples collected ≥ 10 days post symptom onset compared to
364 negatives (**Supplementary Table 1 and Supplementary Table 2**). The median MFI for saliva
365 and serum IgG and IgA to Sino Biol. hCoV 229E ECD was also elevated among samples
366 collected ≥ 10 days post symptom onset compared to negatives (**Supplementary Table 1 and**
367 **Supplementary Table 2**). These results suggest that SARS-CoV-2 elicits cross-reactive

368 antibodies to the closely related SARS-CoV-1, and that reactivity to Sino Biol. hCoV 229E ECD
369 is very common in our study population, likely due to frequent human exposure to hCoVs.

370

371 *Intra- and inter-assay variability*

372 Among 47 saliva samples assayed in duplicate on the same 96-well plate, the average
373 intra-assay variability ranged from 3%-18% (CV%) (**Supplementary Table 3**). Among 47 saliva
374 samples tested in duplicate on different 96-well plates on different days, the average inter-assay
375 variability ranged from 5%-28% (CV%) (**Supplementary Table 3**).

376

377 **Discussion**

378 Our results demonstrate that salivary SARS-CoV-2-specific IgG detection reflects the
379 binding profile observed in serum. Salivary SARS-CoV-2-specific IgG can be used to detect a
380 prior SARS-CoV-2 infection with high sensitivity and specificity. When saliva was collected
381 ≥ 10 days post symptom onset, the anti-SARS-CoV-2 IgG assay detects SARS-CoV-2 infection
382 with 100% sensitivity and 99% specificity (GenScript N) and/or with 89% sensitivity and 100%
383 specificity (Mt. Sinai RBD). In addition, we demonstrate that the temporal kinetics of SARS-
384 CoV-2-specific IgG responses in saliva are consistent with those observed in serum and indicate
385 that most individuals seroconvert approximately 10 days after COVID-19 symptom onset or
386 approximately two weeks post-presumed infection. Based on these results it is feasible to
387 accurately measure the salivary IgG response to identify individuals with a prior SARS-CoV-2
388 infection. Our saliva-based multiplex immunoassay could serve as a non-invasive approach for
389 accurate and large-scale SARS-CoV-2 “sero”-surveillance. Because saliva samples can be self-
390 collected and mailed at ambient temperatures,²⁴ a saliva antibody test could greatly increase the

391 scale of testing—particularly among susceptible populations—compared to blood, and could
392 clarify population immunity and susceptibility to SARS-CoV-2.

393 Matched saliva and serum samples demonstrate a significant correlation in SARS-CoV-2
394 antigen-specific IgG responses. An analysis of temporal kinetics of antibody responses in saliva
395 following COVID-19 symptom onset revealed a congruence with those observed in serum, and a
396 synchronous elevation of SARS-CoV-2 serum IgG and IgM responses, which has been reported
397 in serum.^{14,29-32} In both saliva and serum, IgG rather than IgM was the first isotype to increase,
398 mimicking a response consistent with the stimulation of existing, cross-reactive B cells, even
399 though this is a novel coronavirus in these human populations. Both synchronous and classical
400 antibody isotype responses have been previously reported following SARS-CoV-2 infection.^{14,29-}
401 ³² Furthermore, IgG levels in saliva and serum tended to rise and cross the cut-off around day 10
402 post-COVID-19 symptoms onset, which is typically when individuals seek care from a
403 healthcare provider for the first time. Therefore, salivary antibody testing could be used in
404 combination with standard SARS-CoV-2 nucleic acid diagnostic testing to provide critical
405 information about antibody positivity and temporal kinetics, which can be informative for patient
406 trajectories and outcomes.

407 The sensitivity of our assay improved or remained the same among saliva and serum
408 samples collected during convalescent phase (≥ 10 days post symptom onset) compared to acute
409 phase (< 10 days post symptom onset) for all SARS-CoV-2 antigen-specific IgG, IgA, and IgM.
410 Saliva SARS-CoV-2 antigen-specific IgG peaked at 100% sensitivity, and serum SARS-CoV-2
411 antigen-specific IgG at 92% sensitivity (anti-Sino Biol. RBD IgG and anti-Mt. Sinai RBD IgG,
412 respectively) among samples collected ≥ 10 days post SARS-CoV-2 symptom onset. Earlier

413 studies have reported sensitivities for various SARS-CoV-2 IgG tests peaking at 82%-100%
414 sensitivity among samples collected during convalescent phase of infection.³³⁻³⁵

415 While serum IgA and IgM peaked at 95% and 93% sensitivity, respectively, at ≥ 10 days
416 post symptom onset, saliva IgA and IgM reached a sensitivity of only 61% and 65%,
417 respectively. The median MFI for most SARS-CoV-2 antigen-specific IgA and IgM responses in
418 saliva were, however, significantly elevated at ≥ 10 days post symptom onset compared to
419 negative control samples (**Supplementary Table 1**). One explanation for the low sensitivity
420 observed in saliva for IgA and IgM may be due to the background signal-to-noise ratio for saliva
421 SARS-CoV-2 antigen-specific IgA and IgM, which was greater than that observed for saliva
422 IgG. Non-specific binding of salivary proteins, exogenous particles, non-specific antibodies, or
423 cross-reactivity with other viruses could contribute to this background. Although we harvested
424 GCF, which is enriched with blood transudate, because of size exclusion IgM antibodies are not
425 abundant in saliva (12). Nevertheless, SARS-CoV-2 antigen-specific IgG responses in saliva
426 performed with improved sensitivity and specificity compared to serum, peaking at 100%
427 sensitivity ≥ 10 days post symptom onset for anti-GenScript N IgG and 100% specificity for anti-
428 Mt. Sinai RBD IgG.

429 Virus infections often induce antibody responses that cross-react with related viruses,
430 which can compromise the performance of serologic assays. Cross-reactivity may largely be
431 attributable to the N protein and S2 subunit, which share 90% sequence homology with SARS-
432 CoV-1.³¹ The RBD of the S protein is less conserved across beta-CoVs than the N protein and
433 whole S protein, and many antibodies known to interact with SARS-CoV-1's RBD do not
434 interact with SARS-CoV-2's RBD.³⁸ For these reasons, we hypothesized that SARS-CoV-2 N
435 would be highly sensitive and cross-react with antibodies following SARS-CoV-1 infection,

436 whereas those against SARS-CoV-2 RBD would be more specific.³⁶ We found that all (28/28;
437 100%) saliva samples from COVID-19 cases collected at ≥ 10 days post-symptom onset reacted
438 with NAC SARS 2002 N in the IgG assay, indicating that SARS-CoV-2 infection can elicit
439 cross-reactive IgG to closely related CoVs. Of course, this antigen could still be used for SARS-
440 CoV-2 diagnostics, as the cross-reactivity would only be relevant if SARS-CoV-1 and SARS-
441 CoV-2 were co-circulating in the same human population. We did not specifically evaluate
442 whether common hCoVs elicit cross-reactive antibodies that could cause false positive results in
443 our SARS-CoV-2 assay; however, we did include one hCoV antigen (hCoV-229E ECD) in the
444 panel. Sera from early and late COVID-19 cases and negative control samples all reacted
445 similarly to this antigen, which is consistent with a high prevalence of hCoV exposure in the
446 general population.³⁹⁻⁴¹ This also strongly suggests that our negative control sample population
447 was highly exposed to hCoV and we would not have been able to achieve such clear
448 discrimination between negative control and COVID-19 samples with other antigens in the
449 multiplex panel if cross-reactivity was a significant issue.

450 This study has several limitations. First, our collection of saliva and serum samples was
451 predominantly obtained from independent cohorts, and it contained 28 matched saliva and serum
452 samples collected from the same participants at the same time. In future studies, the performance
453 of this assay should be compared between saliva and serum in a large sample of matched saliva
454 and serum samples. Second, all saliva data was cross sectional and we were not able to evaluate
455 the temporal kinetics of saliva SARS-CoV-2 antibody responses using repeated measures within
456 the same individual. Longitudinal analysis would allow us to evaluate the temporal kinetics and
457 magnitude of SARS-CoV-2 IgG, IgA, and IgM responses, resolve synchronous vs. classical
458 isotype responses (IgM followed by IgA followed by IgG) following SARS-CoV-2 infection.⁴²

459 Additional investigation with convalescent phase saliva and sera are needed to determine the
460 stability of SARS-CoV-2-specific IgG responses. Third, we did not have information on severity
461 of SARS-CoV-2 disease from each participant in this study, and thus were not able to determine
462 the impact of severity of infection on antibody responses.²⁹ Prior studies suggest that antibody
463 responses are slightly elevated among individuals with severe infection.^{29,30,42} Future analysis
464 should determine how severity of infection, and infectious dose, modifies antibody responses.
465 Fourth, we did not determine receiver operating characteristic (ROC)-optimized MFI cut offs in
466 this analysis. However, the cut offs used in this study (average of negatives + three standard
467 deviations) are conservative. Future analysis should identify ROC-optimized cut offs, which
468 could improve the sensitivity and specificity of this saliva assay. Lastly, we did not have
469 sociodemographic and medical history information for participants, and thus were not able to
470 evaluate the relationship of age, sex, and other factors on antibody responses.

471 In future analysis, additional replicates should be used to assess intra- and inter-assay
472 variability, and a lower limit of detection should be determined for each antigen. Furthermore,
473 well characterized sera from other hCoV and zoonotic CoV infections should be used to address
474 potential cross-reactivity of antibodies following SARS-CoV-1, MERS-CoV, hCoV-OC43,
475 hCoV-HKU1, hCoV-229E, and hCoV-NL63 infection with SARS-CoV-2 proteins. Lastly, the
476 performance of this saliva assay should be compared head-to-head with other clinically utilized
477 antibody tests.

478 Saliva represents a practical, non-invasive alternative to NP, OP, blood, and stool-based
479 diagnostic specimens for COVID-19 diagnostic testing. Recently, saliva collection via passive
480 drool (instructing patients to spit into a sterile urine specimen collection cup) was shown to be
481 more sensitive than NP specimens for SARS-CoV-2 RNA detection by RT-PCR in COVID-19

482 patients.²⁶ Furthermore, the U.S. Food and Drug Administration recently granted emergency use
483 authorization for a saliva-based nucleic acid test for SARS-CoV-2 that can be collected at home
484 and mailed in for testing.⁴³ Recognition of the advantages of saliva both for SARS-CoV-2
485 nucleic acid and antibody testing could accelerate goals for nationwide testing to surveil active
486 and prior SARS-CoV-2 infections at the general population level.

487 This study demonstrates that SARS-CoV-2 antigen-specific antibody responses in saliva
488 reflect those observed in serum, and that SARS-CoV-2 antigen-specific IgG can be used to
489 accurately detect prior SARS-CoV-2 infection. We have developed and validated a saliva-based
490 multiplex immunoassay and identified SARS-CoV-2 antigen-specific IgG responses that can
491 detect prior SARS-CoV-2 infection with high sensitivity (anti-N IgG; 100% sensitivity, 99%
492 specificity) and specificity (anti-RBD IgG; 89% sensitivity, 100% specificity) at ≥ 10 days post
493 symptom onset. An accurate saliva-based antibody test for prior SARS-CoV-2 infection would
494 greatly improve our ability to perform public health interventions in the current pandemic. This
495 non-invasive method for comprehensive determination of prior SARS-CoV-2 infection will
496 facilitate large-scale “sero”-surveillance to evaluate population immunity. As SARS-CoV-2
497 vaccine candidates progress through clinical trials, such non-invasive tests will be critical to
498 identify immunity gaps and susceptible populations to inform targeted vaccination efforts, as
499 well as companion diagnostics for vaccine trials.⁴⁴ Furthermore, saliva assays can be used to
500 monitor correlates of protection and the force of transmission in community-based settings, pre-
501 and post- vaccination/prevention strategies, to determine the effectiveness of population-based
502 interventions and direct future preventative strategies.

503

504 **References**

- 505 1. Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard to track COVID-19
506 in real time. *The Lancet Infectious Diseases* **20**, 533-534 (2020).
- 507 2. Angulo, F.J., Finelli, L. & Swerdlow, D.L. Reopening Society and the Need for Real-
508 Time Assessment of COVID-19 at the Community Level. *JAMA* (2020).
- 509 3. Gronvall, G., *et al.* Developing a National Strategy for Serology (Antibody Testing) in
510 the United States. *Johns Hopkins - Bloomberg School of Public Health* (2020).
- 511 4. Bendavid, E., *et al.* COVID-19 Antibody Seroprevalence in Santa Clara County,
512 California. *medRxiv*, 2020.2004.2014.20062463-
513 20062020.20062404.20062414.20062463 (2020).
- 514 5. Sood, N., *et al.* Seroprevalence of SARS-CoV-2-Specific Antibodies Among Adults in
515 Los Angeles County, California, on April 10-11, 2020. *JAMA* (2020).
- 516 6. Cuomo Says 21% of Those Tested in N.Y.C. Had Virus Antibodies. (2020).
- 517 7. Zorzoli, M. ESCLUSIVA I nuovi dati di Robbio, unico paese italiano a fare il test
518 sull'immunità a tutti i cittadini. 70% di asintomatici. (2020).
- 519 8. Regalado, A. Blood tests show 14% of people are now immune to covid-19 in one town
520 in Germany. (2020).
- 521 9. Dyal, J.W., *et al.* COVID-19 Among Workers in Meat and Poultry Processing Facilities -
522 19 States, April 2020. *MMWR. Morbidity and mortality weekly report* **69**(2020).
- 523 10. Lloyd-Sherlock, P., Ebrahim, S., Geffen, L. & McKee, M. Bearing the brunt of covid-19:
524 older people in low and middle income countries. *BMJ* **368**, m1052 (2020).
- 525 11. Ward, C.F., Figiel, G.S. & McDonald, W.M. Altered Mental Status as a Novel Initial
526 Clinical Presentation for COVID-19 Infection in the Elderly. *The American journal of*

- 527 *geriatric psychiatry : official journal of the American Association for Geriatric*
528 *Psychiatry* (2020).
- 529 12. Yang, Y., *et al.* Mental health services for older adults in China during the COVID-19
530 outbreak. *The lancet. Psychiatry* **7**, e19 (2020).
- 531 13. Chandrashekar, A., *et al.* SARS-CoV-2 infection protects against rechallenge in rhesus
532 macaques. *Science*, eabc4776-eabc4776 (2020).
- 533 14. Wajnberg, A., *et al.* Humoral immune response and prolonged PCR positivity in a cohort
534 of 1343 SARS-CoV 2 patients in the New York City region. (2020).
- 535 15. Augustine, S.A.J., *et al.* Developing a Salivary Antibody Multiplex Immunoassay to
536 Measure Human Exposure to Environmental Pathogens. *Journal of Visualized*
537 *Experiments*, 1-7 (2016).
- 538 16. Augustine, S.A.J., *et al.* Immunoprevalence to Six Waterborne Pathogens in Beachgoers
539 at Boqueron Beach, Puerto Rico: Application of a Microsphere-Based Salivary Antibody
540 Multiplex Immunoassay. *Front Public Health* **5**, 84 (2017).
- 541 17. Brandtzaeg, P. Do salivary antibodies reliably reflect both mucosal and systemic
542 immunity? *Annals of the New York Academy of Sciences* **1098**, 288-311 (2007).
- 543 18. Brandtzaeg, P. Secretory immunity with special reference to the oral cavity. *Journal of*
544 *Oral Microbiology* **5**, 1-24 (2013).
- 545 19. Griffin, S.M., Chen, I.M., Fout, G.S., Wade, T.J. & Egorov, A.I. Development of a
546 multiplex microsphere immunoassay for the quantitation of salivary antibody responses
547 to selected waterborne pathogens. *J Immunol Methods* **364**, 83-93 (2011).

- 548 20. Griffin, S.M., *et al.* Application of salivary antibody immunoassays for the detection of
549 incident infections with Norwalk virus in a group of volunteers. *J Immunol Methods* **424**,
550 53-63 (2015).
- 551 21. Pisanic, N., *et al.* Minimally invasive saliva testing to monitor norovirus infection in
552 community settings. *Journal of Infectious Diseases* **219**, 1234-1242 (2019).
- 553 22. Pisanic, N., *et al.* Development of an oral fluid immunoassay to assess past and recent
554 hepatitis E virus (HEV) infection. *Journal of Immunological Methods* **448**, 1-8 (2017).
- 555 23. L.G, W., *et al.* Post-marketing surveillance of OraQuick whole blood and oral fluid rapid
556 HIV testing. *Aids* **20**, 1661-1666 (2006).
- 557 24. Morris-Cunnington, M.C., Edmunds, W.J., Miller, E. & Brown, D.W.G. A population-
558 based seroprevalence study of hepatitis A virus using oral fluid in England and Wales.
559 *American Journal of Epidemiology* **159**, 786-794 (2004).
- 560 25. Lourenco, J., *et al.* Fundamental principles of epidemic spread highlight the immediate
561 need for large-scale serological surveys to assess the stage of the SARS-CoV-2 epidemic.
562 *medRxiv*, 2020.2003.2024.20042291-20042020.20042203.20042224.20042291 (2020).
- 563 26. Wyllie, A.L., *et al.* Saliva is more sensitive for SARS-CoV-2 detection in COVID-19
564 patients than nasopharyngeal swabs. *medRxiv*, 2020.2004.2016.20067835-
565 20062020.20067804.20067816.20067835 (2020).
- 566 27. Sullivan, P.S., *et al.* Detection of SARS-CoV-2 RNA and Antibodies in Diverse Samples:
567 Protocol to Validate the Sufficiency of Provider-Observed, Home-Collected Blood,
568 Saliva, and Oropharyngeal Samples. *JMIR public health and surveillance* **6**, e19054
569 (2020).

- 570 28. To, K.K., *et al.* Temporal profiles of viral load in posterior oropharyngeal saliva samples
571 and serum antibody responses during infection by SARS-CoV-2: an observational cohort
572 study. *Lancet Infect Dis* **20**, 565-574 (2020).
- 573 29. Cervia, C., *et al.* Systemic and mucosal antibody secretion specific to SARS-CoV-2
574 during mild versus severe COVID-19. *bioRxiv*, 2020.2005.2021.108308 (2020).
- 575 30. Guo, L., *et al.* Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease
576 (COVID-19). *Clinical Infectious Diseases* (2020).
- 577 31. Okba, N.M.A., *et al.* Severe Acute Respiratory Syndrome Coronavirus 2–Specific
578 Antibody Responses in Coronavirus Disease 2019 Patients. *Emerging Infectious Diseases*
579 **26**(2020).
- 580 32. Zhao, J., *et al.* Antibody responses to SARS-CoV-2 in patients of novel coronavirus
581 disease 2019. *Clinical Infectious Diseases* (2020).
- 582 33. Lassaunière, R., *et al.* Evaluation of nine commercial SARS-CoV-2 immunoassays.
583 *medRxiv*, 2020.2004.2009.20056325-20052020.20056304.20056309.20056325 (2020).
- 584 34. Whitman, J.D., *et al.* Test performance evaluation of SARS-CoV-2 serological assays.
585 (2020).
- 586 35. Adams, E.R., *et al.* Antibody testing for COVID-19: A report from the National COVID
587 Scientific Advisory Panel. *medRxiv*, 2020.2004.2015.20066407 (2020).
- 588 36. Amanat, F., *et al.* A serological assay to detect SARS-CoV-2 seroconversion in humans.
589 *medRxiv* **2**, 2020.2003.2017.20037713-20032020.20037703.20037717.20037713 (2020).
- 590 37. Kelen, G.D., *et al.* Improvements in the continuum of HIV care in an inner-city
591 emergency department. *AIDS* **30**, 113-120 (2016).

- 592 38. Tian, X., *et al.* Potent binding of 2019 novel coronavirus spike protein by a SARS
593 coronavirus-specific human monoclonal antibody. *Emerging Microbes & Infections* **9**,
594 382-385 (2020).
- 595 39. Monto, A.S. & Lim, S.K. The Tecumseh study of respiratory illness. VI. Frequency of
596 and relationship between outbreaks of coronavirus infection. *J Infect Dis* **129**, 271-276
597 (1974).
- 598 40. Severance, E.G., *et al.* Development of a nucleocapsid-based human coronavirus
599 immunoassay and estimates of individuals exposed to coronavirus in a U.S. metropolitan
600 population. *Clinical and vaccine immunology : CVI* **15**, 1805-1810 (2008).
- 601 41. Gorse, G.J., Patel, G.B., Vitale, J.N. & O'Connor, T.Z. Prevalence of antibodies to four
602 human coronaviruses is lower in nasal secretions than in serum. *Clinical and vaccine*
603 *immunology : CVI* **17**, 1875-1880 (2010).
- 604 42. Long, Q.-X., *et al.* Antibody responses to SARS-CoV-2 in patients with COVID-19.
605 *Nature Medicine* (2020).
- 606 43. FDA. ACCELERATED EMERGENCY USE AUTHORIZATION (EUA) SUMMARY
607 SARS-CoV-2 ASSAY (Rutgers Clinical Genomics Laboratory). Vol. 2020 (US Food and Drug
608 Administration, 2020).
- 609 44. Lipsitch, M., Kahn, R. & Mina, M.J. Antibody testing will enhance the power and
610 accuracy of COVID-19-prevention trials. *Nature Medicine* (2020).

612 **Table 1.** Antigens and antibodies used to develop the multiplex bead-based assay.

<u>Source*</u>	<u>Pathogen</u>	<u>Antigen[#]</u>	<u>Tag</u>	<u>Antibody[^]</u>	<u>Abbreviation</u>	<u>Antigen Catalog No.</u>	<u>Antibody Catalog No.</u>
GenScript		N	his	anti-Gen N	GenScript N	Z03480	A02039
Sino Biol.		N	his	anti-Sino N	Sino Biol. N	40588-V08B	A02039
Sino Biol.		ECD (S1+S2)	his	anti-Sino RBD	Sino Biol. ECD (S1+S2)	40589-V08B1	A02038
Sino Biol.		RBD	his	anti-Sino RBD	Sino Biol. RBD	40592-V08H	40592-T62
Mt. Sinai		RBD	his	anti-Sino RBD	Mt. Sinai RBD	<i>Amanat F., et al</i>	40592-T62
GenScript	SARS-CoV-2	RBD	his	anti-Sino RBD	Sino Biol. RBD (h)	Z03479	40592-T62
GenScript		RBD	his	anti-Sino RBD	Sino Biol. RBD (i)	Z03483	40592-T62
GenScript		S1	N/A	anti-Gen S	GenScript S1	Z03501	A02038
NAC		S1	shFc	anti-Sheep Fc	NAC S1	REC31806	313-005-046
NAC		S2	shFc	anti-Sheep Fc	NAC S2	REC31807	313-005-046
NAC	SARS-CoV-1	SARS CoV N	his	anti-his	NAC SARS 2002 N	REC31744	MA121315
Sino Biol.	hCoV-229E	229E ECD	his	anti-his	Sino Biol. hCoV 229E ECD	40605-V08B	MA121315

*Sino Biol.: Sino Biological; NAC: Native Antigen Company

[#]N: nucleocapsid protein; ECD: ectodomain (S1 + S2 subunit of spike protein); RBD: receptor binding domain

[^]Corresponding IgG antibody used for confirmation

613

614

615 **Table 2.** Saliva and serum samples.

	<u>Saliva</u>		<u>Serum</u>	
	Participants	Samples	Participants	Samples
	n (%)	n (%)	n (%)	n (%)
All samples	150 (100)	167 (100)	171 (100)	324 (100)
SARS-CoV-2 PCR positive	33 (22.0)	33 (19.8)	59 (34.5)	206 (63.6)
SARS-CoV-2 PCR negative	117 (78.0)	134 (80.2)	112 (65.5)	118 (36.4)
<i>Matched saliva-serum samples</i>	28 (100)	28 (100)	-	-
SARS-CoV-2 PCR positive	22 (78.6)	22 (78.6)	-	-
SARS-CoV-2 PCR negative	6 (21.4)	6 (21.4)	-	-

616

617

618

619

620

621

622

623

624

625


626

627

628

629

630



637 subunit+S2 subunit of the spike protein); RBD: receptor binding domain; (h): produced in human
638 cell; (i): produced in insect cell; MFI=mean fluorescence intensity.

639

640

641


642

643

644

645

646



647

648 **Figure 2.** Correlation between saliva and serum SARS-CoV-2 antigen-specific IgA among
 649 matched saliva and serum samples (n=26). Pearson correlation coefficient is provided for each
 650 antigen-specific IgA. *p* values are provided for statistically significant correlations only (*p*<0.05).

651 *Note.* Sino Biol.: Sino Biological; NAC: Native Antigen Company; N: nucleocapsid protein;

652 ECD: S1: S1 subunit of spike protein; S2: S2 subunit of spike protein; ectodomain (S1

653 subunit+S2 subunit of the spike protein); RBD: receptor binding domain; (h): produced in human
654 cell; (i): produced in insect cell; MFI=mean fluorescence intensity.


655

656

657

658

659



660

661 **Figure 3.** Correlation between saliva and serum SARS-CoV-2 antigen-specific IgM among
 662 matched saliva and serum samples (n=26). Pearson correlation coefficient is provided for each
 663 antigen-specific IgM. *p* values are provided for statistically significant correlations only
 664 ($p<0.05$). *Note.* Sino Biol.: Sino Biological; NAC: Native Antigen Company; N: nucleocapsid
 665 protein; ECD: S1: S1 subunit of spike protein; S2: S2 subunit of spike protein; ectodomain (S1

666 subunit+S2 subunit of the spike protein); RBD: receptor binding domain; (h): produced in human
667 cell; (i): produced in insect cell; MFI=mean fluorescence intensity.

668

669

670

671

672

673

674

675

676

677

Antigen	IgG			IgA			IgM			Legend			
	Se	Se	Sp	Se	Se	Sp	Se	Se	Sp				
GenScript N	40%	100%	99%	33%	48%	96%	0%	4%	98%	100%	90%	40%	20%
Sino Biol. N	0%	89%	99%	33%	39%	98%	0%	17%	98%	98%	88%	38%	18%
Sino Biol. ECD	20%	96%	99%	33%	61%	99%	0%	4%	99%	96%	86%	36%	16%
Sino Biol. RBD	20%	96%	99%	0%	17%	99%	0%	30%	98%	94%	84%	34%	14%
Mt. Sinai RBD	0%	89%	100%	0%	26%	99%	0%	35%	98%	92%	82%	32%	12%
GenScript RBD (h)	0%	89%	99%	0%	17%	99%	0%	30%	98%				
GenScript RBD (i)	0%	86%	99%	0%	30%	96%	0%	17%	96%				
NAC S1	0%	57%	99%	0%	8.7%	100%	0%	4%	98%				
GenScript S1	0%	50%	98%	33%	44%	42%	0%	65%	99%				
NAC S2	0%	43%	100%	0%	4%	100%	0%	0%	99%				
NAC SARS 2002 N	20%	100%	99%	33%	44%	98%	0%	4%	96%				

<10 days post symptom onset (n=5) [§]	≥10 days post symptom onset (n=28) [§]	Negative (n=134) [§]	<10 days post symptom onset (n=3) [§]	≥10 days post symptom onset (n=23) [§]	Negative (n=83) [§]	<10 days post symptom onset (n=3) [§]	≥10 days post symptom onset (n=23) [§]	Negative (n=84) [§]				
--	---	-------------------------------	--	---	------------------------------	--	---	------------------------------	--	--	--	--

[§]Not all samples were tested for all isotypes due to limited saliva volume

678

679

680 **Figure 4.** The sensitivity and specificity of each SARS-CoV-2 antigen-specific IgG, IgA, and
681 IgM in saliva. Samples collected from individuals with RT-PCR confirmed prior SARS-CoV-2
682 infection are stratified into samples collected <10 days post symptom onset and samples
683 collected ≥10 days post symptom onset. The average MFI of negative samples + 3 standard
684 deviations was used to set the MFI cut off for each SARS-CoV-2 antigen-specific IgG, IgA, and
685 IgM. Darker shades of green indicate higher whereas darker shades of red indicate lower
686 sensitivity and specificity. *Note.* Sino Biol.: Sino Biological; NAC: Native Antigen Company; N:
687 nucleocapsid protein; ECD: S1: S1 subunit of spike protein; S2: S2 subunit of spike protein;
688 ectodomain (S1 subunit+S2 subunit of the spike protein); RBD: receptor binding domain; (h):

689 produced in human cell; (i): produced in insect cell; Se: Sensitivity; Sp: specificity; MFI=mean
690 fluorescence intensity.

691

692

693

694

695

696

697

698

699

700

Antigen	IgG			IgA			IgM			Legend			
	Se	Sp	Sp	Se	Se	Sp	Se	Se	Sp				
GenScript N	22%	90%	97%	42%	90%	98%	8%	37%	98%	100%	90%	40%	20%
Sino Biol. N	15%	78%	98%	24%	76%	99%	9%	58%	99%	98%	88%	38%	18%
Sino Biol. ECD	21%	89%	96%	36%	90%	96%	21%	82%	98%	96%	86%	36%	16%
Sino Biol. RBD	26%	92%	97%	40%	92%	98%	21%	80%	97%	94%	84%	34%	14%
Mt. Sinai RBD	25%	92%	99%	40%	94%	99%	37%	93%	97%	92%	82%	32%	12%
GenScript RBD (h)	26%	91%	96%	45%	95%	97%	34%	93%	96%				
GenScript RBD (i)	11%	75%	98%	35%	87%	98%	24%	85%	99%				
NAC S1	12%	75%	99%	6%	52%	99%	2%	29%	97%				
GenScript S1	1%	23%	98%	0%	15%	98%	25%	87%	98%				
NAC S2	21%	80%	99%	23%	71%	99%	4%	30%	97%				
NAC SARS 2002 N	21%	89%	96%	46%	95%	99%	11%	51%	99%				
	<10 days post symptom onset (n=92) [§]	≥10 days post symptom onset (n=104) [§]	Negative (n=112) [§]	<10 days post symptom onset (n=92) [§]	≥10 days post symptom onset (n=104) [§]	Negative (n=106) [§]	<10 days post symptom onset (n=92) [§]	≥10 days post symptom onset (n=104) [§]	Negative (n=106) [§]				

[§]Not all samples were tested for all isotypes due to limited serum volume

701
702
703 **Figure 5.** The sensitivity and specificity of each SARS-CoV-2 antigen-specific IgG, IgA, and
704 IgM in serum. Samples collected from individuals with RT-PCR confirmed prior SARS-CoV-2
705 infection are stratified into samples collected <10 days post symptom onset and samples
706 collected ≥10 days post symptom onset. The average MFI of negative samples + 3 standard
707 deviations was used to set the MFI cut off for each SARS-CoV-2 antigen-specific IgG, IgA, and
708 IgM. Darker shades of green indicate higher whereas darker shades of red indicate lower
709 sensitivity and specificity. *Note.* Sino Biol.: Sino Biological; NAC: Native Antigen Company; N:
710 nucleocapsid protein; ECD: S1: S1 subunit of spike protein; S2: S2 subunit of spike protein;
711 ectodomain (S1 subunit+S2 subunit of the spike protein); RBD: receptor binding domain; (h):

712 produced in human cell; (i): produced in insect cell; Se: Sensitivity; Sp: specificity; MFI=mean
713 fluorescence intensity.

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729


730

731

732

733

734



735 **Figure 6.** Comparison of saliva and serum SARS-CoV-2 antigen-specific IgG (red), IgA (blue),
736 and IgM (green) responses vs. days post-COVID-19 symptom onset. The trajectories of IgG
737 (red), IgA (blue), and IgM (green) responses are estimated using a LOESS curve. Dashed lines
738 indicate cut off values for IgG (red), IgA (blue), and IgM (green). *Note.* Sino Biol.: Sino

739 Biological; NAC: Native Antigen Company; N: nucleocapsid protein; ECD: S1: S1 subunit of
740 spike protein; S2: S2 subunit of spike protein; ectodomain (S1 subunit+S2 subunit of the spike
741 protein); RBD: receptor binding domain; (h): produced in human cell; (i): produced in insect
742 cell; MFI=mean fluorescence intensity.